

Special Issue

Herbal Medicine in Cardiovascular Diseases Prevention and Therapy

Message from the Guest Editors

Cardiovascular disease is the leading cause of death throughout the world. Atherosclerotic cardiovascular disease is the major underlying cause. Many effective drugs are available to treat hypertension. Exciting developments have occurred in the field of hyperlipidaemia with the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the development of monoclonal antibodies. Herbal medicines have been used for many types of heart disease for centuries. Obvious examples are digitalis from *Digitalis purpurea* and other foxglove species and salicylates from willows such as *Salix alba*. This Special Issue has been designed to include original research and reviews on herbal medicines that are established or under investigation for the management of cardiovascular diseases and the major risk factors for coronary heart disease and other cardiovascular conditions.

Guest Editors

Prof. Dr. Brian Tomlinson

Faculty of Medicine, Macau University of Science and Technology, Macao, China

Prof. Dr. Paul Chan

Taipei Medical University-Wan Fang Hospital, Taipei Medical University (TMU), Taipei, Taiwan

Deadline for manuscript submissions

closed (31 December 2019)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/27765

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).